PHASE I MOLECULAR AND CLINICAL PHARMACODYNAMIC TRIALS

I 期分子和临床药效试验

• 批准号: 6150170
• 负责人: JAMES H DOROSHOW
• 金额: $ 39.62万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-03-14 至 2003-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6150170
• 关键词: DNA damage; DNA methylation; DNA repair; DNA topoisomerases; antineoplastics; biopsy; cancer registry /resource; cell cycle; chemical kinetics; clinical research; clinical trials; cooperative study; cytotoxicity; drug adverse effect; drug screening /evaluation; gene expression; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; paclitaxel; pharmacokinetics; platinum; tissue resource /registry

DESCRIPTION: (Applicant's Description) The objective of this proposal is to develop new, laboratory-based chemotherapeutic treatment strategies for application in the phase I setting. These phase I studies will lead not only to the assignment of a maximum tolerated dose and to an understanding of the spectrum of normal tissue toxicity for specific antineoplastic agents that target novel molecular pathways, but will also provide a mechanistic evaluation of the effects of the agents on critical tumor cell functions. This objective will be pursued by a group of molecular pharmacologists and clinical scientists from two NCI-designated Cancer Centers and a large University Hospital who will use the extensive laboratory and patient resources of the City of Hope National Medical Center (COH), the Kenneth Norris, Jr. Comprehensive Cancer Center at the University of Southern California (USC), and the University of California, Davis Cancer Center to perform phase I molecular pharmacodynamic studies that focus on: 1) novel compounds which significantly modify patterns of DNA methylation or directly inhibit the activity of DNA methyltransferase as a unique antineoplastic activity; 2) new agents which produce critical alterations in cell cycle checkpoint control or cell cycle progression as their mechanism of action; 3) the role of antineoplastic drug concentration (rather than dose) in the efficacy and toxicity of dose-intensive chemotherapy, as well as the effects of abnormal organ function on the pharmacokinetics and pharmacodynamics of new antineoplastic agents available from the Cancer Therapy Evaluation Program of the NCI; and 4) the identification of new antineoplastic agents available from the Cancer Therapy Evaluation Program of the NCI; and 4) the identification of new molecular correlates of therapeutic activity and drug resistance, including new markers of DNA damage, repair, and methylation, for compounds with novel mechanisms of action, as well as for the taxane, platinum, antimetabolite, and topoisomerase I drug classes. Based on a significant record of patient accrual, as well as substantive clinical, biostatistical, and laboratory interactions during the past three years which have provided the rationale for a novel set of proposed phase I trials, the investigators at COH, USC, and UCD are well suited to rapidly complete pharmacologically-driven phase I trials of anticancer agents targeting critical new intracellular pathways.

描述：(申请人描述)这项建议的目的是 开发以实验室为基础的新的化疗治疗策略 在第一阶段设置中的应用。这些第一阶段的研究不会导致 只对最大耐受量的分配和对 特定抗肿瘤药物的正常组织毒性谱 目标是新的分子途径，但也将提供一种机械性的 评价这些药物对关键肿瘤细胞功能的影响。 这一目标将由一组分子药理学家和 来自NCI指定的两个癌症中心和一个大型癌症中心的临床科学家 大学医院谁将使用广泛的实验室和患者 肯尼斯希望之城国家医疗中心的资源 小诺里斯南方大学综合癌症中心 加州大学戴维斯癌症中心 进行I期分子药效学研究，主要集中在：1)新 显著改变DNA甲基化模式的化合物或直接 抑制DNA甲基转移酶的活性作为一种独特的抗肿瘤药物 活性；2)在细胞周期中产生关键变化的新试剂 检查点控制或细胞周期进程作为其作用机制； 3)抗肿瘤药物浓度(而不是剂量)在 剂量强化化疗的疗效和毒性及其影响 器官功能异常对其药代动力学和药效学的影响 癌症治疗评价中的新型抗肿瘤药物 NCI计划；4)新的抗肿瘤药物的鉴定 可从NCI的癌症治疗评估计划获得；以及4) 新的治疗活性与药物相关分子的鉴定 抗性，包括DNA损伤、修复和甲基化的新标记， 对于具有新作用机制的化合物，以及对于紫杉烷， 铂类、抗代谢药和拓扑异构酶I类药物。基于一个 患者收益和实质性临床记录的显著记录， 过去三年的生物统计学和实验室互动 它们为一套新的拟议第一阶段提供了理论基础 试验，COH、南加州大学和UCD的研究人员非常适合快速 完全药物驱动的抗癌药I期试验 瞄准关键的新细胞内通路。